Lipid Metabolism Is Causal in Some Alzheimer’s Cases

These findings only applied to men without an Alzheimer's-related allele.

by September 19, 2025

Introduction

Recent research published in Aging Cell has shed light on the role of lipid metabolism in the onset of Alzheimer’s disease, specifically in men who do not carry the APOE4 allele, a well-known genetic risk factor for the disease. The study presents compelling evidence that elevated levels of the LPCAT2 enzyme are associated with cognitive decline in this particular demographic group.

Key Findings

  • Elevated levels of the LPCAT2 enzyme are linked to cognitive decline in men lacking the APOE4 allele.
  • A genetic predisposition affects the expression of LPCAT2.
  • These results are not applicable to women or men with the APOE4 allele.

Pain as an Early Sign

Cognitive decline and brain deterioration are hallmark features of Alzheimer’s disease; however, symptoms such as pain sensitivity may emerge early, serving as precursors to cognitive impairment. Previous studies have identified a strong connection between lipid metabolism and pain sensitivity in the context of Alzheimer’s disease. Specifically, lysophosphatidylcholine (LPC) levels have been recognized for their correlation with pain, neuroinflammation, and demyelination associated with the disease.

Research has indicated:

  • Lipid alterations may be among the first detectable changes leading to Alzheimer’s disease.
  • Chronic pain sensitivity increases with mild cognitive impairment in non-APOE4 men.

Research Methodology

To investigate the biological mechanisms linking lipid metabolism and Alzheimer’s, researchers utilized several large databases, including:

  1. The Alzheimer’s Disease Neuroimaging Initiative
  2. The ROSMAP database on memory and aging
  3. A Mayo Clinic gene expression database
  4. The Taiwan Biobank

They complemented these data sources with human brain samples obtained from the NIH to provide a comprehensive analysis of LPCAT2’s role.

Correlation with Pain Sensitivity

The study found compelling associations between LPCAT2 expression and both pain sensitivity and Alzheimer’s onset in men without the APOE4 risk allele. The following table summarizes these findings:

Study Group Pain Sensitivity Genetic Link to LPCAT2
Men without APOE4 Increased with mild cognitive impairment Elevated LPCAT2 found
Women without APOE4 Lower pain sensitivity with cognitive decline Not statistically significant
Men with APOE4 Not analyzed No significant findings

Additionally, tissue analysis revealed that nearly all samples from non-APOE4 men with Alzheimer’s contained elevated LPCAT2 levels. This pattern was mirrored in animal studies, particularly in modified male mice predisposed to Alzheimer’s disease.

Genetic Susceptibility

The investigation into genetic factors revealed that particular single-nucleotide polymorphisms (SNPs) correlated with increased LPCAT2 expression, pain sensitivity, and the risk of Alzheimer's disease. The methodology employed, known as Mendelian randomization, confirmed a causal relationship among these factors.

Potential Mechanisms

The study provides several hypotheses regarding the underlying mechanisms in non-APOE4 men:

  • APOE directly relates to circulating LPC levels.
  • Microglial behavior may influence Alzheimer’s progression.
  • Estrogen levels may modulate this pathway.

It's important to note that the study is observational in nature and does not propose specific methods for altering LPCAT2 levels. Future research is needed to explore whether LPCAT2 can be targeted pharmacologically.

Conclusion

Understanding the implications of lipid metabolism on Alzheimer’s disease, particularly in vulnerable populations such as non-APOE4 men, represents a promising avenue for future research. These findings underscore the necessity of further investigation into potential interventions that could modulate LPCAT2 and its associated pathways.

Support Our Work

We rely on the generosity of our community to continue our mission. All our news and educational content is created free of charge, thanks to your contributions. Whether large or small, every donation supports independent journalism and helps sustain our future endeavors.

Literature Cited

  • [1] Ballard, C., et al. (2011). Alzheimer’s disease. the Lancet, 377(9770), 1019-1031.
  • [2] Zhao, W., et al. (2023). Elevated dementia risk, cognitive decline, and hippocampal atrophy in multisite chronic pain. Proceedings of the National Academy of Sciences, 120(9), e2215192120.
  • [3] Yin, F. (2023). Lipid metabolism and Alzheimer’s disease: clinical evidence, mechanistic link and therapeutic promise. The FEBS journal, 290(6), 1420-1453.
  • [4] Bazan, N. G., et al. (2002). Prostaglandins and other lipid mediators in Alzheimer’s disease. Prostaglandins & other lipid mediators, 68, 197-210.
  • [5] Ren, J., et al. (2022). Lysophosphatidylcholine: Potential target for the treatment of chronic pain. International Journal of Molecular Sciences, 23(15), 8274.
  • [6] Freeman, L., et al. (2017). NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. Journal of Experimental Medicine, 214(5), 1351-1370.
  • [7] Romano, R. R., et al. (2021). Altered evoked pain responsiveness as a biomarker for Alzheimer’s risk? Journal of Alzheimer’s Disease, 79(3), 1227-1233.
  • [8] Aggarwal, N. T., & Mielke, M. M. (2023). Sex differences in Alzheimer’s disease. Neurologic clinics, 41(2), 343.
  • [9] Law, S. H., et al. (2023). Lipidomic profiling reveals lysophosphatidylcholine as a risk factor in mice. International Journal of Molecular Sciences, 24(8), 6956.
  • [10] Yamamoto, S., et al. (2024). Microglial production of transient platelet-activating factor in neuropathic pain. Iscience, 27(4).
  • [11] Karpuzoglu-Sahin, E., et al. (2001). Effects of estrogen treatment on immune response in C57BL/6 mice. Cytokine, 14(4), 208-217.